Maria Palmieri graduated in 2016 with 110/110 cum laude at the University of Siena in molecular and cellular biology. In 2017 she won a Ph.D. fellowship in genetics, oncology and clinical medicine carrying out her research activity in the field of medical oncology at the medical genetics of Prof. Alessandra Renieri under the supervision of Prof. Elisa Frullanti in Siena. Her studies first focused on exploring the genetic basis of lung cancer in young nonsmoking patients and then on applying liquid biopsy in patients with different types of advanced solid tumors. During her Ph.D. years, she introduced and applied the liquid biopsy technique through next-generation sequencing in cancer patients and subsequently in patients suffering from various vascular malformations. The results were shown in various national and international scientific congresses and publications. In December 2020 she obtained her Ph.D. degree with a final mark of excellent cum laude with a thesis entitled “Cell free-DNA-NGS liquid biopsy for solid cancers and vascular malformations”. In January 2021 she won a post-doctoral fellowship from the department of medical biotechnology on “CRISPR / cas9 gene editing for the treatment of PCDH19 mutation disease.” Her research work is accompanied by 30 scientific articles, 7 of which as the first author, on the application of liquid biopsy in cancer patients in order to discover therapeutic targets for personalized medicine.
Maria Palmieri graduated in 2016 with 110/110 cum laude at the University of Siena in molecular and cellular biology. In 2017 she won a Ph.D. fellowship in genetics, oncology and clinical medicine carrying out her research activity in the field of medical oncology at the medical genetics of Prof. Alessandra Renieri under the supervision of Prof. Elisa Frullanti in Siena. Her studies first focused on exploring the genetic basis of lung cancer in young nonsmoking patients and then on applying liquid biopsy in patients with different types of advanced solid tumors. During her Ph.D. years, she introduced and applied the liquid biopsy technique through next-generation sequencing in cancer patients and subsequently in patients suffering from various vascular malformations. The results were shown in various national and international scientific congresses and publications. In December 2020 she obtained her Ph.D. degree with a final mark of excellent cum laude with a thesis entitled “Cell free-DNA-NGS liquid biopsy for solid cancers and vascular malformations”. In January 2021 she won a post-doctoral fellowship from the department of medical biotechnology on “CRISPR / cas9 gene editing for the treatment of PCDH19 mutation disease.” Her research work is accompanied by 30 scientific articles, 7 of which as the first author, on the application of liquid biopsy in cancer patients in order to discover therapeutic targets for personalized medicine.